Considering the restrictions of prevailing therapies, we have identified the novel feature of DMF in combating allergic asthma by reducing the production of pro-inflammatory cytokines, i.e., IL4, IL13, and IL17, in the bronchoalveolar tissue. This evidence concerns the gene IL17A and allergic asthma.